August 25th, 2016|
Otsuka America Pharmaceutical, Inc. has finally made changes to the label for the prescription drug Abilify® at the instruction of the FDA in a warning posted on May 3, 2016.
The new detailed Abilify label warning suggests that “patients can experience intense urges, particularly for gambling, and the inability to control these urges while taking aripiprazole. Other compulsive urges, reported less frequently include: sexual urges, shopping, eating or binge eating, and other impulsive or compulsive behaviors.” Read the full label here.
Abilify is an anti-psychotic commonly prescribed to treat mental disorders, such as bipolar disorder, schizophrenia, and severe depression. Many of these patients are often times susceptible to the side effects listed in the new warning because they may have a difficult time linking the compulsive behaviors to the medication. Therefore, it is incumbent on the manufacturers of Abilify to help patients and doctors identify the link between this side effect and Abilify usage. This is highlighted in the warning where it says that “patients may not recognize such behaviors as abnormal,” and the company “counsels physicians to ask about such behaviors and recommends discontinuation or dose reduction if behaviors arise.”
Get Help With Your Abilify® Lawsuit
If you or someone you love has developed a compulsive gambling habit after taking Abilify, you may be entitled to compensation. Contact the experienced drug injury lawyers at Cory Watson Attorneys today to get the help you deserve. Don’t wait to reach out – call now at (877) 562-0000 or fill out our free initial consultation form.
Do not stop taking any medication without consulting your doctor. Abilify® is a registered trademark of Bristol-Myers Squibb and Otsuka America Pharmaceutical, and is used here only to identify the product in question.
This law firm is not associated with, sponsored by, or affiliated with Bristol-Myers Squibb Company; The British Journal of Psychology; Otsuka Pharmaceutical Co., Ltd.; or the U.S. Food and Drug Administration.